EXELIXIS INC (EXEL) Stock Fundamental Analysis
USA - NASDAQ:EXEL - US30161Q1040 - Common Stock
38.72 USD
+0.67 (+1.76%)
39 USD
+0.28 (+0.72%)
We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 534 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
Each year in the past 5 years EXEL has been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.
1.2 Ratios
EXEL has a better Return On Assets (22.49%) than 97.00% of its industry peers.
With an excellent Return On Equity value of 29.62%, EXEL belongs to the best of the industry, outperforming 97.19% of the companies in the same industry.
EXEL has a better Return On Invested Capital (25.22%) than 98.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is below the industry average of 15.49%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(25.22%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROIC | 25.22% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
The Profit Margin of EXEL (27.01%) is better than 96.07% of its industry peers.
In the last couple of years the Profit Margin of EXEL has declined.
EXEL's Operating Margin of 33.71% is amongst the best of the industry. EXEL outperforms 97.57% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
The Gross Margin of EXEL (96.59%) is better than 96.07% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
EXEL has less shares outstanding than it did 1 year ago.
EXEL has less shares outstanding than it did 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 11.73 indicates that EXEL is not in any danger for bankruptcy at the moment.
EXEL has a better Altman-Z score (11.73) than 84.46% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.73 |
ROIC/WACC2.69
WACC9.36%
2.3 Liquidity
EXEL has a Current Ratio of 3.51. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.51, EXEL is in line with its industry, outperforming 41.01% of the companies in the same industry.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
EXEL's Quick ratio of 3.44 is in line compared to the rest of the industry. EXEL outperforms 41.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.74%, which is quite impressive.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.73%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
3.2 Future
EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.20% yearly.
The Revenue is expected to grow by 10.31% on average over the next years. This is quite good.
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXEL is valuated rather expensively with a Price/Earnings ratio of 18.62.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.51% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.91. EXEL is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.32, the valuation of EXEL can be described as correct.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.07% of the companies in the same industry.
EXEL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 13.32 |
4.2 Price Multiples
95.88% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
97.00% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.82 | ||
| EV/EBITDA | 11.52 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 25.84% in the coming years.
PEG (NY)0.63
PEG (5Y)1.47
EPS Next 2Y25.34%
EPS Next 3Y25.84%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
38.72
+0.67 (+1.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner Change-0.26%
Ins Owners2.23%
Ins Owner Change-2.59%
Market Cap10.42B
Revenue(TTM)2.23B
Net Income(TTM)602.30M
Analysts76.92
Price Target45.2 (16.74%)
Short Float %6.74%
Short Ratio6.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-0.16%
PT rev (3m)-3.44%
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)1.12%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 13.32 | ||
| P/S | 4.67 | ||
| P/FCF | 13.82 | ||
| P/OCF | 13.5 | ||
| P/B | 5.13 | ||
| P/tB | 5.29 | ||
| EV/EBITDA | 11.52 |
EPS(TTM)2.08
EY5.37%
EPS(NY)2.91
Fwd EY7.51%
FCF(TTM)2.8
FCFY7.23%
OCF(TTM)2.87
OCFY7.41%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.63
PEG (5Y)1.47
Graham Number18.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROCE | 32.1% | ||
| ROIC | 25.22% | ||
| ROICexc | 38.09% | ||
| ROICexgc | 39.72% | ||
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% | ||
| FCFM | 33.81% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 60.32% | ||
| Cap/Sales | 0.81% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.79% | ||
| Profit Quality | 125.2% | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 11.73 |
F-Score8
WACC9.36%
ROIC/WACC2.69
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 18.62 and the Price/Book (PB) ratio is 5.13.